课题基金 / 基金详情

Using markers to improve pancreatic cancer screening and surveillance

Using markers to improve pancreatic cancer screening and surveillance
使用标记物改善胰腺癌筛查和监测
批准号:
10427584
负责人:
Michael G. Goggins
金额:
$93.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-18 至 2023-06-30

项目摘要

项目成果

Michael G. Goggins的其他基金

相似基金

相关文献

中文摘要
翻译
由于大多数胰腺癌患者都有晚期疾病,因此需要进行胰腺筛查 发现无症状的早期潜在可治愈的病变。在我们的胰腺癌筛查中(CAPS) 我们已经对大约600名患胰腺癌风险增加的人进行了临床研究, 家族史或基因突变标准。筛查可以识别癌前病变和胰腺癌, 但需要更好的循环和胰液标记物来辅助胰腺评估。胰液 在常规内窥镜超声检查中从十二指肠收集的样本显示,该样本是丰富的 胰腺肿瘤的生物标志物和胰液分析可能是一项有用的诊断试验。因此, GNAS突变对IPMN具有高度特异性,在慢性支气管炎患者的果汁样本中特异性检测到 IPMN。KRAS基因突变不仅在胰腺癌患者的胰液中常见 癌症,但在接受胰腺筛查的患者中,即使他们没有胰腺疾病的证据 通过影像检查肿瘤。这些突变中的许多被认为是在Panin中出现的,而不是通过 胰腺成像检查,因为这些病变非常小,不会形成肿块。因此,胰液 分析有可能表明Panin的存在。更有价值的是一项测试,它将表明 胰腺肿瘤的级别,因为在没有癌症的情况下,这通常是无法确定的 而不对切除的胰腺进行分析。我们知道TP53和Smad4突变出现在高级别 胰液中可发现TP53和Smad4突变 胰腺癌和高度不典型增生患者的样本,而不是疾病对照组或低级别非典型增生患者的样本。 重度不典型增生。为了进一步评估候选诊断标记物,我们建议:目标1:确定 胰液中检测突变作为胰腺癌和胰腺癌标志物的诊断准确性 癌前病变。我们将使用新的NextGen测序方法来检测慢性粒细胞白血病患者的突变 胰腺癌、IPMNS、慢性胰腺炎或正常胰腺。目标2:评估循环标志物 作为早期发现胰腺癌的诊断试验。我们将评估ctDNA和外体标记。 目的#3:评估胰液和血清标志物作为检测Panin-3和/或临床前的试验 接受胰腺筛查和监测的高危个体中的胰腺癌。我们会 建立珍贵样本的组织资料库,以协助评估候选胰腺癌 标记物,包括来自高危受试者和Panin-3病变的样本。
英文摘要
Since most patients with pancreatic cancer present with advanced disease, pancreatic screening is needed to detect asymptomatic early-stage potentially curable lesions. In our CAncer of the Pancreas Screening (CAPS) clinical studies we have screened ~600 individuals at increased risk of developing pancreatic cancer using family history or gene mutation criteria. Screening can identify precancerous lesions and pancreatic cancers, but better circulating and pancreatic juice markers are needed to aid in pancreatic evaluation. Pancreatic juice collected from the duodenum during routine endoscopic ultrasound reveals that this sample is a rich source of biomarkers of pancreatic neoplasia and the analysis of pancreatic juice could be a useful diagnostic test. Thus, GNAS mutations are highly specific for IPMNs are specifically detected in the juice samples of patients with IPMNs. KRAS mutations are commonly found not only in the pancreatic juice of patients with pancreatic cancer, but in patients undergoing pancreatic screening even when they do not have evidence of pancreatic neoplasia by imaging. Many of these mutations are thought to arise in PanIN, which are not detected by pancreatic imaging tests because these lesions are very small and do not form masses. Thus, pancreatic juice analysis has the potential to indicate the presence of PanIN. More valuable would be a test that would indicate the grade of pancreatic neoplasia since in the absence of cancer, this is usually not possible to determine without analyzing the resected pancreas. We know that TP53 and SMAD4 mutations emerge in high-grade dysplasia and invasive pancreatic cancer tumors and can find TP53 and SMAD4 mutations in pancreatic juice samples in patients with pancreatic cancer and high-grade dysplasia, not in disease controls or those with low- grade dysplasia. To further evaluate candidate diagnostic markers we propose: Aim #1: To determine the diagnostic accuracy of mutations detected in pancreatic fluid as markers of pancreatic cancer and precancerous lesions. We will use novel nextgen sequencing methods to detect mutations in patients with pancreatic cancer, IPMNs, chronic pancreatitis, or normal pancreata. Aim #2: To evaluate circulating markers as diagnostic tests for the early detection of pancreatic cancer. We will evaluate ctDNA and exosomal markers. Aim #3: To evaluate pancreatic fluid and serum markers as tests to detect PanIN-3 and/or pre-clinical pancreatic cancer among high-risk individuals undergoing pancreatic screening and surveillance. We will develop a tissue repository of precious samples to aid in the evaluation of candidate pancreatic cancer markers, including samples from high-risk subjects and PanIN-3 lesions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Using markers to improve pancreatic cancer screening and surveillance: a multi-center study
  • 批准号:
    10701743
  • 项目类别:
  • 资助金额:
    $54.46万
  • 财政年份:
    2016
  • 负责人:
    Michael G. Goggins
  • 依托单位:
Using markers to improve pancreatic cancer screening and surveillance: a multi-center study
  • 批准号:
    10526649
  • 项目类别:
  • 资助金额:
    $78.66万
  • 财政年份:
    2016
  • 负责人:
    Michael G. Goggins
  • 依托单位:
Using Markers to Improve Pancreatic Cancer Screening
  • 批准号:
    8589991
  • 项目类别:
  • 资助金额:
    $41.67万
  • 财政年份:
    2013
  • 负责人:
    Michael G. Goggins
  • 依托单位:
Using Markers to Improve Pancreatic Cancer Screening
  • 批准号:
    9054087
  • 项目类别:
  • 资助金额:
    $41.67万
  • 财政年份:
    2013
  • 负责人:
    Michael G. Goggins
  • 依托单位:
海外基金